erlotinib has been researched along with diclofenac sodium in 1 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (diclofenac sodium) | Trials (diclofenac sodium) | Recent Studies (post-2010) (diclofenac sodium) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 104 | 0 | 64 |
| Protein | Taxonomy | erlotinib (IC50) | diclofenac sodium (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 2.6367 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.82 | |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | 2.6 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 3.2667 | |
| Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | 0.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arafa, RK; El-Sayed, NA; Nour, MS; Salem, MA | 1 |
1 other study(ies) available for erlotinib and diclofenac sodium
| Article | Year |
|---|---|
New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Models, Molecular; Molecular Structure; Oxadiazoles; Protein Kinase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |